期刊文献+

胃腺癌组织中血管活性肠肽及其受体mRNA的表达研究 被引量:1

MRNA EXPRESSION OF VASOACTIVE INTESTINAL PEPTIDE AND ITS RECEPTOR IN GASTRIC ADENOCARCINOMA
下载PDF
导出
摘要 目的:研究血管活性肠肽(VIP)及其受体(VIPR)mRNA在胃腺癌组织中的表达情况,探讨其在胃腺癌发病过程中的作用。方法:通过RT-PCR方法,检测32例胃腺癌组织(胃腺癌组)、33例不典型增生胃黏膜组织(不典型增生组)和24例正常胃腺组织(正常对照组)中VIP及VIPR mRNA的表达。结果:3组胃腺组织的VIP mRNA表达率均为100.00%。胃腺癌组的VIP mRNA的相对表达量均高于正常对照组和不典型增生组(P<0.01),正常对照组和不典型增生组之间比较差异无统计学意义(P>0.05)。正常对照组、胃腺癌组和不典型增生组VIPR1 mRNA表达率依次为83.33%(20/24)、43.75%(14/32)和60.61%(20/33),3组间比较差异有统计学意义(P<0.05);VIPR2 mRNA表达率在正常对照组、胃腺癌组和不典型增生组依次为66.67%(16/24)、50.00%(16/32)和57.59%(19/33),3组间比较差异无统计学意义(P>0.05)。胃腺癌组的VIPR1mRNA的相对表达量均低于不典型增生组和正常对照组(P<0.01),而正常对照组和不典型增生组之间比较差异无统计学意义(P>0.05);VIPR2 mRNA的相对表达量在不同组间比较差异无统计学意义(P>0.05)。结论:胃腺癌组织中VIP mRNA的表达量高于正常胃黏膜和不典型增生胃黏膜组织,但VIPR1mRNA的表达量却低于正常胃黏膜和不典型增生胃黏膜组织,VIP可能与胃腺癌的发生发展有关。 Objective: To investigate mrna expression of vasoactive intestinal peptide and its receptor in gas- tric adenocarcinoma and understand the effect of VIP and VIPR on gastric adenocarcinoma and possible mechanism. Methods: Gastric tissues of 32 patients with gastric adenocarcinoma, 33 patients with dysplasia and 24 healthy controls were collected, and mrna expression of vasoactive intestinal peptide and its receptor in gastric adenocarcinoma were determined by real time PCR. Results: All of the gastric tissues among the three groups were positive in VIP mRNA expression. The levels of VIP mRNA in gastric adenocarcinoma was higher than that in dysplasia and controls ( P〈0.01), while there was no difference between the dys-plasia and the rate of VIPR1 controls ( P〉0.05). The mRNA was 83.33%(20/24 expression ) in gastric lower than 60.61% (20/ :NA didn' t adenocarcinoma, which was significantly dysplasia 43.75% (14/32) and controls 60 33)(P 〈0.05), but that of VIPR2 mRchanged significantly (66. 67% vs 50.00% and 57.59%) ( P 〉0.05). The levels of VIPR1 mRNA in gas- tric adenocarcinoma was lower than that in dysplasia and controls ( P〈0.01), while there was no differ- ence between the dysplasia and the controls ( P〉0.05). There was no difference in the levels of VIPR2 mRNA among the three groups ( P〉0.05). Conclusion: The expression of VIP mRNA in gastric adeno- carcinoma was higher than that in dysplasia and controls, while VIPR1 mRNA was lower than the two groups, so they might contribute to the diagnosis of gastric carcinoma. VIP might play an important role in the pathogenesis and progress of gastric adenocarcinoma.
出处 《广西医科大学学报》 CAS 2015年第1期73-76,共4页 Journal of Guangxi Medical University
基金 广西壮族自治区卫生厅自筹经费科研课题(No.Z2011349)
关键词 胃腺癌 血管活性肽 血管活性肽受体 gastric adenocarcinoma vasoactive intestinal peptide vasoactive intestinal peptide receptor
  • 相关文献

参考文献11

二级参考文献40

  • 1宁军,龚浩.胃癌患者T淋巴细胞和NK细胞检测的临床意义[J].临床和实验医学杂志,2006,5(9):1292-1293. 被引量:9
  • 2李国华,钱伟,王静,侯晓华.胃腺癌细胞中血管活性肠肽自分泌调节作用及其机制[J].中华消化杂志,2005,25(1):27-31. 被引量:8
  • 3王伟,李伟毅.血管活性肠肽的免疫调节作用[J].细胞生物学杂志,2005,27(2):148-152. 被引量:15
  • 4Xie Y, Wolff DW, Lin MF, et al. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells[J]. Mol Pharmacol,2007, 72(1): 73-85.
  • 5Heasley LE. Autocrine and paracrine signaling through neuropeptide receptors in human cancer[J]. Oncogene, 2001, 20(13): 1563-1569.
  • 6Iwanaga T. Vasoactive intestinal polypeptide (VIP)[J]. Nippon Rinsho, 2002, 60 Suppl 6: 35-38.
  • 7Tzaneva MA. Endocrine cells in gastric carcinoma and adjacent mucosa. An immunohistochemical and ultrastructural study[J]. Histochem J, 2002, 34(3-4): 173-180.
  • 8Li GH, Qian W, Song GQ, et al. Effect of vasoactive intestinal peptide on gastric adenocarcinoma[J]. J Gastroenterol Hepatol, 2007, 22(8): 1328-1335.
  • 9Iishi H, Tatsuta M, Baba M, et al. Enhancement by vaso-active intestinal peptide of gastric carcinogenesis induced by N-methyl-N' -nitro-N - nitrosoguanidine in rats[J]. Int J Cancer, 1992, 50(4): 649-652.
  • 10Delgado M, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas figand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3[J]. J Immunol, 2001, 166(2):1028-1040.

共引文献34

同被引文献8

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部